Media headlines about Celldex Therapeutics (NASDAQ:CLDX) have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Celldex Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 47.554218359895 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Shares of Celldex Therapeutics (NASDAQ:CLDX) opened at $2.93 on Wednesday. Celldex Therapeutics has a 52-week low of $2.20 and a 52-week high of $4.12.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.07. The company had revenue of $3.90 million during the quarter, compared to analysts’ expectations of $1.30 million. Celldex Therapeutics had a negative net margin of 1,088.58% and a negative return on equity of 46.94%. Celldex Therapeutics’s quarterly revenue was up 77.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.29) earnings per share. research analysts expect that Celldex Therapeutics will post -0.93 earnings per share for the current fiscal year.

Several equities analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Celldex Therapeutics in a report on Tuesday, August 1st. ValuEngine downgraded shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $9.00 price objective on shares of Celldex Therapeutics in a report on Tuesday, September 26th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $6.31.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Celldex Therapeutics (CLDX) Stock Price” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Insider Buying and Selling by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Stock Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related stocks with our FREE daily email newsletter.